DossierENTITY

cancer drug sales

Coverage of cancer drug sales in the Nexus archive.

Earliest in view: Jul 27 · 12:00 UTCMost recent: Jul 27 · 12:00 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJul 27 · 12:00 UTCQUARTZ
AstraZeneca's profit beat expectations as cancer drug sales powered growth
AstraZeneca's core earnings per share increased to $2.63 in Q2, exceeding analyst expectations of $2.48. The company attributed the growth to strong cancer drug sales and maintained its full-year and 2030 outlooks.